There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunome (IMNM) and COMPASS Pathways (CMPS) with bullish sentiments.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Immunome (IMNM)
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Immunome, with a price target of $40.00. The company’s shares closed last Friday at $23.35, close to its 52-week high of $25.75.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of 26.8% and a 64.5% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Parabilis Medicines, Inc., Revolution Medicines, and Compass Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Immunome with a $35.36 average price target, representing a 46.3% upside. In a report issued on June 29, J.P. Morgan also maintained a Buy rating on the stock.
